Clinical Trial Update: Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF） [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating tolerability, pharmacokinetics, and preliminary efficacy of ZSP1603 in idiopathic pulmonary fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• ZSP1603

Snippet

Sponsor: Guangdong Raynovent Biotech Co., Ltd | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 1, Phase 2 | Status: COMPLETED